On May 28, 2014, Vital Therapies, Inc. (NASDAQ: VTL), announced financial results for the quarter ended March 31, 2014, and provided an update on recent operations.Vital Therapies Inc (NASDAQ:VTL) weekly performance is -26.85%. On last trading day company shares ended up $23.49. Analysts mean target price for the company is $21.00. Vital Therapies Inc (NASDAQ:VTL) distance from 50-day simple moving average (SMA50) is 49.22%.
Law Offices of Howard G. Smith announces that it is investigating potential claims on behalf of investors of Northwest Biotherapeutics, Inc (NASDAQ:NWBO). The investigation concerns possible violations of federal securities laws and focuses on certain statements issued by Northwest Biotherapeutics concerning the Company’s operations and prospects. Northwest Biotherapeutics, Inc (NASDAQ:NWBO) shares fell -19.96% in last trading session and ended the day on $7.18. NWBO return on assets is -943.30%. Northwest Biotherapeutics, Inc (NASDAQ:NWBO) quarterly performance is -4.90%.
Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) was a big mover last session,. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the uptrend for the company, as the stock is now up roughly 44% in the past one-month timeframe. Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) shares moved down -8.36% in last trading session and was closed at $44.60, while trading in range of $44.05 – $490.70. Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) year to date (YTD) performance is 5.56%.
On June 9, 2014, Galmed Pharmaceuticals Ltd (NASDAQ:GLMD), announced that it filed a provisional patent application in the United States for the use of its drug, aramchol, for the treatment of lipodystrophy. Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) ended the last trading day at $9.20. Company weekly volatility is calculated as 7.08% and price to cash ratio as 1021.20. Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) showed a negative weekly performance of -7.72%.
Zalicus Inc. (NASDAQ:ZLCS), announced that it has licensed its Sodium Channel Modulator program, including intellectual property and related pipeline assets, to AnaBios Corporation in exchange for clinical milestone payments and royalties on potential future sales. Under the terms of the agreement Zalicus will be eligible to receive up to $17.2 million in clinical and regulatory milestone payments and up to 12% of net sales on any future products resulting from this license. Zalicus Inc (NASDAQ:ZLCS) shares moved down -5.18% in last trading session and was closed at $1.28, while trading in range of $1.26 – $1.350. Zalicus Inc (NASDAQ:ZLCS) year to date (YTD) performance is 15.32%.
Leave a Reply